GlaxoSmithKline/£GSK
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About GlaxoSmithKline
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
£GSK
Sector
Primary listing
LSE
Employees
68,629
Headquarters
Website
GlaxoSmithKline Metrics
BasicAdvanced
£65B
19.63
£0.83
0.29
£0.62
3.82%
Price and volume
Market cap
£65B
Beta
0.29
52-week high
£16.85
52-week low
£12.43
Average daily volume
8.4M
Dividend rate
£0.62
Financial strength
Current ratio
0.867
Quick ratio
0.555
Long term debt to equity
106.618
Total debt to equity
120.9
Dividend payout ratio (TTM)
72.80%
Interest coverage (TTM)
10.25%
Profitability
EBITDA (TTM)
9,291
Gross margin (TTM)
71.69%
Net profit margin (TTM)
10.82%
Operating margin (TTM)
20.13%
Effective tax rate (TTM)
13.80%
Revenue per employee (TTM)
£460,000
Management effectiveness
Return on assets (TTM)
6.78%
Return on equity (TTM)
28.33%
Valuation
Price to earnings (TTM)
19.631
Price to revenue (TTM)
2.091
Price to book
4.43
Price to tangible book (TTM)
-8.96
Price to free cash flow (TTM)
13.652
Free cash flow yield (TTM)
7.32%
Free cash flow per share (TTM)
1.188
Dividend yield (TTM)
3.82%
Growth
Revenue change (TTM)
0.59%
Earnings per share change (TTM)
-15.48%
3-year revenue growth (CAGR)
4.37%
10-year revenue growth (CAGR)
3.09%
3-year earnings per share growth (CAGR)
-9.68%
10-year earnings per share growth (CAGR)
-10.43%
3-year dividend per share growth (CAGR)
-9.94%
10-year dividend per share growth (CAGR)
-4.52%
What the Analysts think about GlaxoSmithKline
Analyst ratings (Buy, Hold, Sell) for GlaxoSmithKline stock.
Bulls say / Bears say
GSK’s Specialty Medicines segment fueled a 6% rise in Q2 2025 sales at constant exchange rates to £8 billion, as strong double-digit gains in respiratory, immunology, oncology, and HIV products prompted the company to project full-year sales and profit at the upper end of its guidance (Reuters).
In January 2025, GSK acquired U.S. biotech company IDRx for up to $1.15 billion, gaining global rights to a range of gastrointestinal cancer assets and strengthening its oncology pipeline through focused business development (Reuters).
In February 2025, GSK announced a £2 billion share buyback and raised its 2031 sales goal to over £40 billion, crediting this upgrade to substantial late-stage pipeline progress—especially in oncology—which underscores management’s confidence in the company’s long-term growth outlook (Bloomberg).
GSK’s vaccine division continues to struggle, with its RSV vaccine Arexvy bringing in just £0.1 billion in Q1 2025—a 57% year-over-year drop—which contributed to a 6% decrease in overall vaccine sales and highlights ongoing weakness in this business segment (Reuters).
Analysts predict GSK will reach only £34 billion in revenue by 2031—15% under management’s £40 billion goal—showing significant doubt about the company’s ability to achieve its stated growth targets without major breakthroughs (Reuters Breakingviews).
GSK’s leading HIV drug, dolutegravir, will lose patent protection from 2028 in the U.S., putting nearly 20% of the company’s current revenue at risk and raising the threat of a significant revenue gap if upcoming products fail to perform or are delayed (Reuters Breakingviews).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
GlaxoSmithKline Financial Performance
Revenues and expenses
GlaxoSmithKline Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GlaxoSmithKline stock?
GlaxoSmithKline (GSK) has a market cap of £65B as of October 09, 2025.
What is the P/E ratio for GlaxoSmithKline stock?
The price to earnings (P/E) ratio for GlaxoSmithKline (GSK) stock is 19.63 as of October 09, 2025.
Does GlaxoSmithKline stock pay dividends?
Yes, the GlaxoSmithKline (GSK) stock pays dividends to shareholders. As of October 09, 2025, the dividend rate is £0.62 and the yield is 3.82%. GlaxoSmithKline has a payout ratio of 72.8% on a trailing twelve-month basis.
When is the next GlaxoSmithKline dividend payment date?
The next GlaxoSmithKline (GSK) dividend payment is scheduled for October 09, 2025.
What is the beta indicator for GlaxoSmithKline?
GlaxoSmithKline (GSK) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.